维得利珠单抗一线及后线治疗炎症性肠病的疗效比较
Comparison of the efficacy of Vedolizumab on inflammatory bowel disease in the first and not line treatments
方洒 1吴开春 2时永全 2王玉龙 2韩霜 3陈敏2
作者信息
- 1. 西安交通大学附属红会医院消化内科,陕西 西安 710054;空军军医大学第一附属医院消化内科
- 2. 空军军医大学第一附属医院消化内科
- 3. 西安交通大学附属红会医院消化内科,陕西 西安 710054
- 折叠
摘要
目的 评估维得利珠单抗(Vedolizumab,VDZ)作为一线生物制剂治疗炎症性肠病(inflammatory bowel disease,IBD)患者的疗效和安全性.方法 回顾性分析 2021 年 2 月至 2022 年 5 月空军军医大学第一附属医院使用 VDZ 治疗 IBD 患者的临床资料.比较既往未使用生物制剂治疗的患者与既往使用生物制剂治疗患者使用 VDZ 的治疗效果.结果 共 32 例使用 VDZ 治疗 IBD 患者纳入研究,其中 VDZ为一线生物制剂组占 43.8%(14/32),VDZ为后线生物制剂组占 56.3%(18/32).在第 6 周、14 周、22 周、52周时,两组临床应答率差异无统计学意义(P均>0.05);在 22 周、52 周时,VDZ为一线生物制剂组临床缓解率均高于 VDZ为后线生物制剂组(P<0.05).在 22 周、52 周时,两组内镜应答率差异无统计学意义(P 均>0.05);在 22 周时,VDZ 为一线生物制剂组内镜缓解率高于VDZ为后线生物制剂组(P=0.009).随访期间仅VDZ为后线生物制剂组出现 1 例过敏性皮疹.结论 VDZ作为一线生物制剂在短期内对 IBD具有较好的诱导临床及内镜缓解作用,安全性高.
Abstract
Objective To evaluate the efficacy and safety of Vedolizumab(VDZ)as a first-line biological agent in the treatment of patients with inflammatory bowel disease(IBD).Methods The clinical data of IBD patients treated with VDZ in the First Affiliated Hospital of Air Force Military Medical University from Feb.2021 to May 2022 was ana-lyzed retrospectively.The efficacy of VDZ treatment was compared between patients who have not previously been treated with biological agents group B and who have previously been treated with biological agents(group A).Results A total of 32 patients with IBD treated with VDZ were screened,with group A accounting for 43.8%(14/32)and group B ac-counting for 56.3%(18/32).At 6,14,22 and 52 weeks,there was no statistically significant difference in clinical re-sponse rates between the two groups(all P>0.05).At 22 and 52 weeks,the clinical response rates of group A were higher than those of group B(P<0.05).At 22 and 52 weeks,there was no statistically significant difference in endo-scopic response rates between the two groups(both P>0.05).At 22 weeks,the endoscopic response rate in group A higher than that in group B(P=0.009).During the follow-up period,only one case of allergic rash occurred in group B.Conclusion VDZ as a first-line biological agent,has a good inducing clinical and endoscopic relief effect on IBD in the short term,with high safety.
关键词
维得利珠单抗/炎症性肠病/溃疡性结肠炎/克罗恩病/疗效/安全性Key words
Vedolizumab/Inflammatory bowel disease/Ulcerative colitis/Crohn's disease/Efficacy/Security引用本文复制引用
出版年
2024
NETL
NSTL
万方数据